Flawed, scandalous trials tank FDA expert support for MDMA therapy
Bias, missing data, and claims of a new-age cult overshadow positive patient results.
![Flawed, scandalous trials tank FDA expert support for MDMA therapy](https://cdn.arstechnica.net/wp-content/uploads/2024/06/GettyImages-566464211-760x380.jpeg)
![MDMA pills up close.](https://cdn.arstechnica.net/wp-content/uploads/2024/06/GettyImages-566464211-800x552.jpeg)
Enlarge / MDMA pills up close. (credit: Getty | Universal History Archive)
After a remarkably sensational regulatory drug review, advisers for the Food and Drug Administration on Tuesday voted overwhelmingly against approving midomafetamine (MDMA, aka ecstasy or molly) as part of therapy for post-traumatic stress disorder.
In a response to the question, "Do the available data show that the drug is effective in patients with posttraumatic stress disorder?" advisers voted 9 "no" to 2 "yes" against MDMA.
The votes come after a full-day meeting in which the independent expert advisers heard detailed reviews of clinical trial data from the company that proposed the therapy—Lykos, formerly MAPS—as well as internal FDA reviews.
What's Your Reaction?
![like](https://todaypic.com/assets/img/reactions/like.png)
![dislike](https://todaypic.com/assets/img/reactions/dislike.png)
![love](https://todaypic.com/assets/img/reactions/love.png)
![funny](https://todaypic.com/assets/img/reactions/funny.png)
![angry](https://todaypic.com/assets/img/reactions/angry.png)
![sad](https://todaypic.com/assets/img/reactions/sad.png)
![wow](https://todaypic.com/assets/img/reactions/wow.png)